menu
    • menu
    [{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"PROTACs","year":"2025","type":"Inapplicable","leadProduct":"ARV-102","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"||Hydrolytic enzyme","graph1":"Neurology","graph2":"Phase I","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BTG Specialty Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cullgen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CG001419","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Cullgen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cullgen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cullgen \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Latigo Biotherapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"LTG-001","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Latigo Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Latigo Biotherapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Latigo Biotherapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Elysium Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"O2P Hydrocodone Prodrug","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Elysium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elysium Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elysium Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"MAXONA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nefopam Hydrochloride","moa":"Dopamine\/serotonin\/norepinephrine Reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"MAXONA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MAXONA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MAXONA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Chromocell Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Diclofenac","moa":"COX-1\/COX2","graph1":"Neurology","graph2":"Phase I","graph3":"Benuvia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Spray","sponsorNew":"Benuvia Therapeutics \/ Chromocell Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Benuvia Therapeutics \/ Chromocell Corporation"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VK0214","moa":"TR-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LX1001","moa":"APOE-2\/APOE-3","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Cerveau Technologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Cerveau Technologies","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"ALN-APP","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Cerveau Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Cerveau Technologies \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Cerveau Technologies \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alector","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Termination","leadProduct":"AL003","moa":"CD33","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ AbbVie Inc"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halozyme Therapeutics \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Halozyme Therapeutics \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Citigroup","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Citigroup"},{"orgOrder":0,"company":"APRINOIA Therapeutics","sponsor":"ROSS Acquisition Corp II","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Termination","leadProduct":"APNmAb005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"APRINOIA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II","highestDevelopmentStatusID":"6","companyTruncated":"APRINOIA Therapeutics \/ ROSS Acquisition Corp II"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VY-TAU01","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Alzheimer's Memory Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Sabirnetug","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Alzheimer\\'s Memory Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alzheimer\\'s Memory Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzheimer\\'s Memory Center \/ Inapplicable"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Axoltis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"NX210c","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InSilicoTrials \/ Axoltis Pharma","highestDevelopmentStatusID":"6","companyTruncated":"InSilicoTrials \/ Axoltis Pharma"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VY7523","moa":"C-terminal epitope Tau","graph1":"Neurology","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Regeneration Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RB-ADSC","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Regeneration Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intraventricular Infusion","sponsorNew":"Regeneration Biomedical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regeneration Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LHP588","moa":"Gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lighthouse Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"DGX-001","moa":"AVPR1A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Viage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Viage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Samus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icapamespib","moa":"Epichaperome","graph1":"Neurology","graph2":"Phase I","graph3":"Samus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Samus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Samus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VG-3927","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"PF-05251749","moa":"CK1","graph1":"Neurology","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pfizer Inc \/ Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Biogen"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HT-4253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Yale University"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Orphan Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Orphan Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Jupiter Orphan Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Orphan Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ National Institute on Aging"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Inapplicable"},{"orgOrder":0,"company":"Oligomerix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"OLX-07010","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Oligomerix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oligomerix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Oligomerix \/ Undisclosed"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Neuronascent","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-362","moa":"S6K1","graph1":"Neurology","graph2":"Phase I","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Liquid Suspension","sponsorNew":"Neuronascent \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Neuronascent \/ National Institute on Aging"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Neurology","graph2":"Phase I","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Linical","sponsor":"Alpha Cognition","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Linical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Linical \/ Alpha Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Linical \/ Alpha Cognition"},{"orgOrder":0,"company":"Walgreens","sponsor":"Prothena","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Collaboration","leadProduct":"PRX012","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase I","graph3":"Walgreens","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Walgreens \/ Prothena","highestDevelopmentStatusID":"6","companyTruncated":"Walgreens \/ Prothena"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NDX-1017","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"NDX-1017","moa":"HGF receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Athira Pharma \/ Perceptive Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Perceptive Advisors"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Aliada Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Acquisition","leadProduct":"ALIA-1758","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Aliada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aliada Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Aliada Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMRA-511","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neumora therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ EQT Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ EQT Life Sciences"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"QRL-201","moa":"STMN2","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"BIIB078","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biogen \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CK0803","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Abatacept","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"COYA 302","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NB-4746","moa":"SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ Inapplicable"},{"orgOrder":0,"company":"Nura Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"Caffeine","moa":"||SARM1","graph1":"Neurology","graph2":"Phase I","graph3":"Nura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nura Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Nura Bio \/ The Column Group"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Ferrer Internacional"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"PGC-1-alpha","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"eIF2B","graph1":"Neurology","graph2":"Phase I","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Massachusetts General Hospital","highestDevelopmentStatusID":"6","companyTruncated":"AbbVie Inc \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CVN293","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Financing","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stealth Biotherapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"ProJenX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prosetin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"ProJenX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ProJenX \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ProJenX \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Athira Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ATH-1105","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Athira Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athira Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Athira Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AMX0114","moa":"CAPN2","graph1":"Neurology","graph2":"Phase I","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"QurAlis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"QRL-101","moa":"Kv7.2\/Kv7.3","graph1":"Neurology","graph2":"Phase I","graph3":"QurAlis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QurAlis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"QurAlis \/ Inapplicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"||GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Harrow"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RP-2000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Bioresearch","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Fencamfamine Prodrug","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Bioresearch","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Bioresearch \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Bioresearch \/ National Institutes of Health"},{"orgOrder":0,"company":"DeFloria","sponsor":"AJNA BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"AJA001","moa":"CB receptor","graph1":"Neurology","graph2":"Phase I","graph3":"DeFloria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"DeFloria \/ AJNA BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"DeFloria \/ AJNA BioSciences"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"||Bacteria microbiome","graph1":"Neurology","graph2":"Phase I","graph3":"Scioto Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scioto Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Scioto Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lys-MDA","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"6","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"ART26.12","moa":"FABP5","graph1":"Neurology","graph2":"Phase I","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Artelo Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Artelo Biosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"EicOsis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Kindeva Drug Delivery","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Kindeva Drug Delivery"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Inapplicable"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Nutriband","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Nutriband","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Nutriband \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nutriband \/ Undisclosed"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kindeva Drug Delivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Kindeva Drug Delivery \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Kindeva Drug Delivery \/ Nutriband"},{"orgOrder":0,"company":"Veranova","sponsor":"Nutriband","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Veranova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Veranova \/ Nutriband","highestDevelopmentStatusID":"6","companyTruncated":"Veranova \/ Nutriband"},{"orgOrder":0,"company":"Contineum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PIPE-791","moa":"LPA1","graph1":"Neurology","graph2":"Phase I","graph3":"Contineum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Contineum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Contineum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Neurology","graph2":"Phase I","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Biopharmaceutical Research Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Biopharmaceutical Research Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biopharmaceutical Research Company \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biopharmaceutical Research Company \/ Inapplicable"},{"orgOrder":0,"company":"Lighthouse Pharmaceuticals","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"COR588","moa":"Lysine gingipain","graph1":"Neurology","graph2":"Phase I","graph3":"Lighthouse Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lighthouse Pharmaceuticals \/ Quince Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lighthouse Pharmaceuticals \/ Quince Therapeutics"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Alkem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Alkem Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Alkem Laboratories"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"SON-081","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ New Life Therapeutics"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"New Life Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2021","type":"Licensing Agreement","leadProduct":"Atexakin Alpha","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ New Life Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ New Life Therapeutics"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Eight Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Eight Capital","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Eight Capital"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bright Minds Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bright Minds Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bright Minds Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bright Minds Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Epygenix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Epygenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epygenix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epygenix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PRAX-628","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ENX-101","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Trevena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Trevena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Inapplicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"180 Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"180 Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"180 Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Avenue Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BAER-101","moa":"GABAA-alpha-2\/3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avenue Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Avenue Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avenue Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase I","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Precision Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Allopregnanolone","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PureTech Health \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ US Department of Defense"},{"orgOrder":0,"company":"Alector","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AL101","moa":"Gamma-secretase","graph1":"Neurology","graph2":"Phase I","graph3":"Alector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alector \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alector \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Neurology","graph2":"Phase I","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anavex Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Anavex Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Chardan"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Chardan","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"COYA 301","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Chardan","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Chardan"},{"orgOrder":0,"company":"Cerevance","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CVN293","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Cerevance","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerevance \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cerevance \/ Inapplicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Vanqua Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VQ-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vanqua Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanqua Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vanqua Bio \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder in Sachet","sponsorNew":"Gain Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"IMAC Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IMAC Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"IMAC Holdings \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IMAC Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series B Financing","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Vida Ventures LLC","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"VGL101","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Morgan Stanley","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Morgan Stanley"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-313","moa":"CGRP receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Ceruvia Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"2-Bromo-Lysergic Acid Diethylamide","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Ceruvia Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ceruvia Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ceruvia Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Pulmatrix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Mannkind \/ Pulmatrix","highestDevelopmentStatusID":"6","companyTruncated":"Mannkind \/ Pulmatrix"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Dihydroergotamine Mesylate","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pulmatrix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pulmatrix \/ Inapplicable"},{"orgOrder":0,"company":"Nuvie Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"NVI-100","moa":"CGRPR","graph1":"Neurology","graph2":"Phase I","graph3":"Nuvie Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nuvie Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvie Bio \/ Inapplicable"},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1076986","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dianthus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"DNTH103","moa":"C1","graph1":"Neurology","graph2":"Phase I","graph3":"Dianthus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dianthus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dianthus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ingenu","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"Hypercitrullination","graph1":"Neurology","graph2":"Phase I","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ingenu \/ FSD Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ingenu \/ FSD Pharma"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"},{"orgOrder":0,"company":"Sudo Biosciences","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"SUDO-550","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sudo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sudo Biosciences \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sudo Biosciences \/ Enavate Sciences"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"LPX-TI641","moa":"TIM-3\/TIM-3","graph1":"Neurology","graph2":"Phase I","graph3":"LAPIX Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LAPIX Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"LAPIX Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Inmagene Biopharmaceuticals","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IMG-004","moa":"BTK","graph1":"Neurology","graph2":"Phase I","graph3":"Inmagene Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Inmagene Biopharmaceuticals \/ Hutchmed","highestDevelopmentStatusID":"6","companyTruncated":"Inmagene Biopharmaceuticals \/ Hutchmed"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ Inapplicable"},{"orgOrder":0,"company":"Trethera","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TRE-515","moa":"dCK","graph1":"Neurology","graph2":"Phase I","graph3":"Trethera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Trethera \/ UCLA","highestDevelopmentStatusID":"6","companyTruncated":"Trethera \/ UCLA"},{"orgOrder":0,"company":"Halia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HT-6184","moa":"NEK7","graph1":"Neurology","graph2":"Phase I","graph3":"Halia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Halia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Halia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Alumis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"A-005","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Alumis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alumis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alumis \/ Inapplicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ATA188","moa":"T-cell receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Neurology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kyverna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abata Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"ABA-101","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Abata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abata Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Abata Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Neurology","graph2":"Phase I","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"ERP Biomarker Qualification Consortium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"ERP Biomarker Qualification Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ERP Biomarker Qualification Consortium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ERP Biomarker Qualification Consortium \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1065890","moa":"VMAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NBI-1117567","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NBI-1117569","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avata Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Avata Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avata Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Avata Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Quolet Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Quolet Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Quolet Industries \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Quolet Industries \/ Inapplicable"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Nan Fung Life Sciences"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Nan Fung Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"ENX-101","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Engrail Therapeutics \/ Nan Fung Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Engrail Therapeutics \/ Nan Fung Life Sciences"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NBI-1140675","moa":"VMAT2","graph1":"Neurology","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"KCP506","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kineta \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Genentech"},{"orgOrder":0,"company":"Kineta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"KCP506","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kineta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Inapplicable"},{"orgOrder":0,"company":"Kineta","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2025","type":"Agreement","leadProduct":"KCP506","moa":"nACh receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Kineta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kineta \/ Pacira BioSciences","highestDevelopmentStatusID":"6","companyTruncated":"Kineta \/ Pacira BioSciences"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund Ii","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"CB2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii"},{"orgOrder":0,"company":"EicOsis","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"EicOsis","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EC5026","moa":"sEH","graph1":"Neurology","graph2":"Phase I","graph3":"EicOsis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"EicOsis \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"6","companyTruncated":"EicOsis \/ National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diethylamide","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"STC-004","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SiteOne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"STC-004","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"SiteOne Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Inapplicable"},{"orgOrder":0,"company":"South Rampart Pharma","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetaminophen Analog","moa":"COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"South Rampart Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"South Rampart Pharma \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"South Rampart Pharma \/ Quotient Sciences"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-961","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Xanomeline","moa":"||M1\/M4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Karuna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sparian Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SBS-1000","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Sparian Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sparian Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sparian Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"ST-2427","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SiteOne Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"BlueRock Therapeutics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DA01","moa":"Dopaminergic cell","graph1":"Neurology","graph2":"Phase I","graph3":"BlueRock Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"BlueRock Therapeutics \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"BlueRock Therapeutics \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Inapplicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-312","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Vaxxinity \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FGF-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray, Metered","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Zhittya Genesis Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"FGF-1","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Zhittya Genesis Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Spray, Metered","sponsorNew":"Zhittya Genesis Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhittya Genesis Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Alkahest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"AKST4290","moa":"CXCR-3 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Alkahest","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alkahest \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alkahest \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DNL201","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arvinas","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ARV-102","moa":"LRRK2","graph1":"Neurology","graph2":"Phase I","graph3":"Arvinas","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arvinas \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arvinas \/ Inapplicable"},{"orgOrder":0,"company":"Adhera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Adhera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adhera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adhera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"GT-02287","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Innosuisse","highestDevelopmentStatusID":"6","companyTruncated":"Gain Therapeutics \/ Innosuisse"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Yumanity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Proteostasis Therapeutics \/ Yumanity Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Proteostasis Therapeutics \/ Yumanity Therapeutics"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Yumanity Therapeutics","sponsor":"Proteostasis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"YTX-7739","moa":"SCD","graph1":"Neurology","graph2":"Phase I","graph3":"Yumanity Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yumanity Therapeutics \/ Proteostasis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Yumanity Therapeutics \/ Proteostasis Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"Melior Pharmaceuticals","sponsor":"Adhera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Armesocarb","moa":"Dopamine reuptake","graph1":"Neurology","graph2":"Phase I","graph3":"Melior Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Melior Pharmaceuticals \/ Adhera Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Melior Pharmaceuticals \/ Adhera Therapeutics"},{"orgOrder":0,"company":"Neuropore Therapies","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NPT520-34","moa":"SLC22A8","graph1":"Neurology","graph2":"Phase I","graph3":"Neuropore Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neuropore Therapies \/ Celerion","highestDevelopmentStatusID":"6","companyTruncated":"Neuropore Therapies \/ Celerion"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allyx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Olatec Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Olatec Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Neurology","graph2":"Phase I","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Olatec Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Olatec Therapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Dominari Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Dominari Securities","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Dominari Securities"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Zina Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Jupiter Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Jupiter Neurosciences \/ Zina Biopharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Jupiter Neurosciences \/ Zina Biopharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Jupiter Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Resveratrol","moa":"Angiogenesis","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Catalent Pharma Solutions \/ Jupiter Neurosciences","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Jupiter Neurosciences"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Funding","leadProduct":"SBT-272","moa":"TDP-43 aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TB006","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Utreloxastat","moa":"15-LOX","graph1":"Neurology","graph2":"Phase I","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appello Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AP-472","moa":"mGlu4 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Appello Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appello Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Appello Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Timbetasin Acetate","moa":"Angiopoietin-1","graph1":"Neurology","graph2":"Phase I","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RegeneRx Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RegeneRx Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kannalife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KLS-13019","moa":"mNCX-1","graph1":"Neurology","graph2":"Phase I","graph3":"Kannalife","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kannalife \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kannalife \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Batoclimab","moa":"FcRn","graph1":"Neurology","graph2":"Phase I","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"BBP-671","moa":"Glycolate oxidase","graph1":"Neurology","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Axonis Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AXN-027","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Axonis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axonis Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Axonis Therapeutics \/ Cormorant Asset Management"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Diazepam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Xeris Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Graviton Bioscience","sponsor":"Ovid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"GV101","moa":"ROCK2","graph1":"Neurology","graph2":"Phase I","graph3":"Graviton Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Graviton Bioscience \/ Ovid Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Graviton Bioscience \/ Ovid Therapeutics"},{"orgOrder":0,"company":"RApport","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"RApport","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RApport \/ Third Rock Ventures","highestDevelopmentStatusID":"6","companyTruncated":"RApport \/ Third Rock Ventures"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rapport Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"6","companyTruncated":"Rapport Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"OV329","moa":"GABA-AT","graph1":"Neurology","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"N-Desethyloxybutynin","moa":"Muscarinic receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Neos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Orally Disintegrating","sponsorNew":"Neos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeurOp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NP10679","moa":"GluN2B","graph1":"Neurology","graph2":"Phase I","graph3":"NeurOp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NeurOp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeurOp \/ Inapplicable"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Neurology","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pinteon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ironwood Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"IW-3300","moa":"Guanylate cyclase C","graph1":"Neurology","graph2":"Phase I","graph3":"Ironwood Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Rectal Enema","sponsorNew":"Ironwood Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ironwood Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"AMX0114","moa":"CAPN2","graph1":"Neurology","graph2":"Phase I","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Amylyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amylyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VRG50635","moa":"PIKfyve","graph1":"Neurology","graph2":"Phase I","graph3":"Verge Genomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Verge Genomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verge Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Coya Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Abatacept","moa":"||IL-2 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Coya Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Coya Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Coya Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ketamine Analog","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mira Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mira Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"VG-3927","moa":"TREM2","graph1":"Neurology","graph2":"Phase I","graph3":"Vigil Neuroscience","amount2":0.46999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.46999999999999997,"dosageForm":"Oral","sponsorNew":"Vigil Neuroscience \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Vigil Neuroscience \/ Sanofi"},{"orgOrder":0,"company":"SiteOne Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"STC-004","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Phase I","graph3":"SiteOne Therapeutics","amount2":1,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":1,"dosageForm":"Oral Suspension","sponsorNew":"SiteOne Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"SiteOne Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Radiprodil","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"GRIN Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.56999999999999995,"dosageForm":"Oral Suspension","sponsorNew":"GRIN Therapeutics \/ Angelini Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GRIN Therapeutics \/ Angelini Pharma"},{"orgOrder":0,"company":"Vima Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VIM0423","moa":"mAChR","graph1":"Neurology","graph2":"Phase I","graph3":"Vima Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Vima Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Vima Therapeutics \/ Atlas Venture"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Veranova

                            U.S.A
                            ChemOutsourcing
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothVeranova: A CDMO that manages complexity with confidence.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Nutriband

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nutriband Licenses Bitrex for AVERSA Fentanyl Transdermal Patch

                            Details : Nutriband signs licensing agreement for Bitrex (denatonium benzoate) as an aversive agent for its Aversa Fentanyl (Fentanyl) abuse deterrent fentanyl transdermal patch.

                            Product Name : Aversa

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            September 20, 2024

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Nutriband

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Veranova

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosigotifator

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigational Drug ABBV-CLS-7262 Initiates Design Phase For Entry Into The HEALEY ALS Platform Trial

                            Details : ABBV-CLS-7262 targets eIF2B, a key regulator of the ISR, a pathway activated in people with ALS. In neurons exposed to cellular stressors, inhibition of the ISR by ABBV-CLS-7262 restores protein synthesis and dissolves pre-formed TDP-43 containing stress...

                            Product Name : ABBV-CLS-7262

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 07, 2022

                            Lead Product(s) : Fosigotifator

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vima Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Vima Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VIM0423

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Atlas Venture

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Vima Therapeutics Launches First Oral Therapy for Dystonia and Movement Disorders

                            Details : Vima is advancing VIM0423, a potential first-in-class oral therapy for dystonia that targets the underlying cause in the central nervous system.

                            Product Name : VIM0423

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 29, 2025

                            Lead Product(s) : VIM0423

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Atlas Venture

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SiteOne Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            SiteOne Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STC-004

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Expand its Pain Pipeline with Acquisition of SiteOne Therapeutics

                            Details : The acquisition of SiteOne Therapeutics includes STC-004, a next-generation, Phase 2 ready Nav1.8 inhibitor being studied as non-opioid treatment for patients suffering from chronic pain.

                            Product Name : STC-004

                            Product Type : Other Small Molecule

                            Upfront Cash : $1,000.0 million

                            May 27, 2025

                            Lead Product(s) : STC-004

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : $1,000.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            GRIN Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            GRIN Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Angelini Pharma

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GRIN and Angelini Partner to Develop Radiprodil Globally Except North America

                            Details : Angelini Pharma will receive exclusive rights to commercialize radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders, outside north america.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : $50.0 million

                            May 27, 2025

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Angelini Pharma

                            Deal Size : $570.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GRIN Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            GRIN Therapeutics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GRIN gets EU Orphan Designation for Radiprodil in GRIN Neurodevelopmental Disorder

                            Details : Radiprodil is a potent negative allosteric modulator of the NMDA receptor subtype 2B. It is being evaluated for seizures associated with GRIN-related neurodevelopmental disorder with GoF mutations.

                            Product Name : RGH-896

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 06, 2025

                            Lead Product(s) : Radiprodil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mira Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Mira Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Analog

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MIRA Reports No Brain Toxicity for Ketamir-2 in FDA-Required Study

                            Details : Ketamir-2 is a novel oral ketamine analog, a NMDA receptor antagonist, being investigated for Neuropathic Pain.

                            Product Name : Ketamir-2

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 06, 2025

                            Lead Product(s) : Ketamine Analog

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Amylyx Pharmaceuticals

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMX0114

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amylyx Doses First ALS Patient in Phase 1 LUMINA Trial of AMX0114

                            Details : AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2) for the potential treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : AMX0114

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : AMX0114

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Verge Genomics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Verge Genomics

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VRG50635

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verge Finds ALS Digital Biomarkers in VRG50635 Pre-Treatment Run-In Period

                            Details : VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE, Verge’s all-in-human, AI-powered platform.

                            Product Name : VRG50635

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2025

                            Lead Product(s) : VRG50635

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arvinas

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Arvinas

                            U.S.A arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARV-102

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arvinas Presents Data for PROTAC ARV-102, Demonstrating Blood-Brain Barrier Penetration

                            Details : ARV-102 is a novel oral PROTAC degrader designed to cross the blood-brain barrier and target LRRK2. It is being evaluated for the treatment of parkinson disease & progressive supranuclear palsy.

                            Product Name : ARV-102

                            Product Type : PROTACs

                            Upfront Cash : Inapplicable

                            April 04, 2025

                            Lead Product(s) : ARV-102

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth